TSM Taiwan Semiconductor: Is $500 Next? 5 Key Stock Moves After Q3 Surge 🚀
1 extracted signal · 0 resolved · 1 still active
StockInvest.usIndependent analyst profile- Source published
- 28 Oct 2026, 23:14 UTC
- Recorded by Tahlil Plus
- 29 Oct 2026, 00:18 UTC
AI-generated source summary
The analysis indicates mixed signals for TSM, with a short-term buy signal from the Moving Average Convergence Divergence (MACD) and a general sell signal from the long-term average. The stock's current price is above its short-term moving averages, suggesting bullishness, but faces resistance at $440.97. A break above this level could signal further gains. Conversely, support is found at $426.94. The MACD has issued a buy signal from a pivot point identified on October 22, 2026, indicating a potential rise. However, volume decreased on the last trading day, which may be an early warning of price changes. The stock's 3-month and 12-month outlooks suggest potential growth, with projected returns of 2.21% to 54.54% respectively. The P/E ratio of 27.53 is considered typical for companies with consistent growth. The stock's recent performance shows a 2.37% weekly volatility and trades within a medium-risk profile.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.